Advertisement

Journal of Neuro-Oncology

, Volume 139, Issue 1, pp 77–88 | Cite as

Neuroimaging classification of progression patterns in glioblastoma: a systematic review

  • Rory J. Piper
  • Keerthi K. Senthil
  • Jiun-Lin Yan
  • Stephen J. Price
Clinical Study

Abstract

Background

Our primary objective was to report the current neuroimaging classification systems of spatial patterns of progression in glioblastoma. In addition, we aimed to report the terminology used to describe ‘progression’ and to assess the compliance with the Response Assessment in Neuro-Oncology (RANO) Criteria.

Methods

We conducted a systematic review to identify all neuroimaging studies of glioblastoma that have employed a categorical classification system of spatial progression patterns. Our review was registered with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) registry.

Results

From the included 157 results, we identified 129 studies that used labels of spatial progression patterns that were not based on radiation volumes (Group 1) and 50 studies that used labels that were based on radiation volumes (Group 2). In Group 1, we found 113 individual labels and the most frequent were: local/localised (58%), distant/distal (51%), diffuse (20%), multifocal (15%) and subependymal/subventricular zone (15%). We identified 13 different labels used to refer to ‘progression’, of which the most frequent were ‘recurrence’ (99%) and ‘progression’ (92%). We identified that 37% (n = 33/90) of the studies published following the release of the RANO classification were adherent compliant with the RANO criteria.

Conclusions

Our review reports significant heterogeneity in the published systems used to classify glioblastoma spatial progression patterns. Standardization of terminology and classification systems used in studying progression would increase the efficiency of our research in our attempts to more successfully treat glioblastoma.

Keywords

Glioblastoma Progression Recurrence Pattern Neuroimaging 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

11060_2018_2843_MOESM1_ESM.docx (141 kb)
Supplementary material 1 (DOCX 142 KB)
11060_2018_2843_MOESM2_ESM.docx (130 kb)
Supplementary material 2 (DOCX 130 KB)
11060_2018_2843_MOESM3_ESM.docx (126 kb)
Supplementary material 3 (DOCX 126 KB)
11060_2018_2843_MOESM4_ESM.docx (123 kb)
Supplementary material 4 (DOCX 124 KB)
11060_2018_2843_MOESM5_ESM.docx (120 kb)
Supplementary material 5 (DOCX 120 KB)
11060_2018_2843_MOESM6_ESM.docx (222 kb)
Supplementary material 6 (DOCX 222 KB)
11060_2018_2843_MOESM7_ESM.docx (260 kb)
Supplementary material 7 (DOCX 260 KB)
11060_2018_2843_MOESM8_ESM.docx (268 kb)
Supplementary material 8 (DOCX 267 KB)

References

  1. 1.
    Ostrom QT, Gittleman H, Xu J et al (2016) CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2009–2013. Neuro Oncol 18:v1–v75PubMedGoogle Scholar
  2. 2.
    Price SJ, Gillard JH (2011) Imaging biomarkers of brain tumour margin and tumour invasion. Br J Radiol 84:S159–S167PubMedPubMedCentralGoogle Scholar
  3. 3.
    Friedmann-Morvinski D (2014) Glioblastoma heterogeneity and cancer cell plasticity. Crit Rev Oncog 19:327–336PubMedGoogle Scholar
  4. 4.
    Zhang W, Le TD, Liu L et al (2017) Mining heterogeneous causal effects for personalized cancer treatment. Bioinformatics 33:2372–2378PubMedGoogle Scholar
  5. 5.
    Filippini G, Falcone C, Boiardi A et al (2008) Prognostic factors for survival in 676 consecutive patients with newly diagnosed primary glioblastoma. Neuro Oncol 10:79–87PubMedPubMedCentralGoogle Scholar
  6. 6.
    Hochberg FH, Pruitt A (1980) Assumptions in the radiotherapy of glioblastoma. Neurology 30:907–911PubMedGoogle Scholar
  7. 7.
    Brandes AA, Tosoni A, Franceschi E et al (2009) Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 27:1275–1279PubMedGoogle Scholar
  8. 8.
    De Bonis P, Anile C, Pompucci A et al (2013) The influence of surgery on recurrence pattern of glioblastoma. Clin Neurol Neurosurg 115:37–43PubMedGoogle Scholar
  9. 9.
    Kim J, Lee I-H, Cho HJ et al (2015) Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell 28:318–328PubMedGoogle Scholar
  10. 10.
    Wen PY, Macdonald DR, Reardon DA et al (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28:1963–1972PubMedGoogle Scholar
  11. 11.
    Ellingson BM, Wen PY, Cloughesy TF (2017) Modified criteria for radiographic response assessment in glioblastoma clinical trials. Neurotherapeutics 14:307–320PubMedPubMedCentralGoogle Scholar
  12. 12.
    Bähr O, Harter PN, Weise LM et al (2014) Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma. Neurology 83:227–234PubMedGoogle Scholar
  13. 13.
    Choi SH, Kim JW, Chang JS et al (2017) Impact of including peritumoral edema in radiotherapy target volume on patterns of failure in glioblastoma following temozolomide-based chemoradiotherapy. Sci Rep 7:42148PubMedPubMedCentralGoogle Scholar
  14. 14.
    Lundemann M, Costa JC, Law I et al (2017) Patterns of failure for patients with glioblastoma following O-(2-[(18)F]fluoroethyl)-l-tyrosine PET- and MRI-guided radiotherapy. Radiother Oncol 122:380–386PubMedGoogle Scholar
  15. 15.
    Fujimura M, Kumabe T, Jokura H et al (2004) Intractable vomiting as an early clinical symptom of cerebrospinal fluid seeding to the fourth ventricle in patients with high-grade astrocytoma. J Neurooncol 66:209–216PubMedGoogle Scholar
  16. 16.
    Blumenthal DT, Artzi M, Liberman G et al (2017) Classification of high-grade glioma into tumor and nontumor components using support vector machine. Am J Neuroradiol 38:908–914PubMedGoogle Scholar
  17. 17.
    Cachia D, Elshafeey NA, Kamiya-Matsuoka C et al (2017) Radiographic patterns of progression with associated outcomes after bevacizumab therapy in glioblastoma patients. J Neurooncol 135:75–81PubMedGoogle Scholar
  18. 18.
    Rapp M, Baernreuther J, Turowski B et al (2017) Recurrence pattern analysis of primary glioblastoma. World Neurosurg 103:733–740PubMedGoogle Scholar
  19. 19.
    Straube C, Elpula G, Gempt J et al (2017) Re-irradiation after gross total resection of recurrent glioblastoma: spatial pattern of recurrence and a review of the literature as a basis for target volume definition. Strahlenther Onkol 193:897–909PubMedGoogle Scholar
  20. 20.
    Lutterbach J, Guttenberger R, Pagenstecher A (2001) Gliosarcoma: a clinical study. Radiother Oncol 61:57–64PubMedGoogle Scholar
  21. 21.
    Sneed PK, McDermott MW, Gutin PH (1997) Interstitial brachytherapy procedures for brain tumors. Semin Surg Oncol 13:157–166PubMedGoogle Scholar
  22. 22.
    Khalifa J, Tensaouti F, Lusque A et al (2017) Subventricular zones: new key targets for glioblastoma treatment. Radiat Oncol 12:67PubMedPubMedCentralGoogle Scholar
  23. 23.
    Kondo N, Barth RF, Miyatake S-I et al (2017) Cerebrospinal fluid dissemination of high-grade gliomas following boron neutron capture therapy occurs more frequently in the small cell subtype of IDH1(R132H) mutation-negative glioblastoma. J Neurooncol 133:107–118PubMedPubMedCentralGoogle Scholar
  24. 24.
    Agarwal A, Kumar S, Narang J et al (2013) Morphologic MRI features, diffusion tensor imaging and radiation dosimetric analysis to differentiate pseudo-progression from early tumor progression. J Neurooncol 112:413–420PubMedGoogle Scholar
  25. 25.
    Agbi CB, Bernstein M, Laperriere N et al (1992) Patterns of recurrence of malignant astrocytoma following stereotactic interstitial brachytherapy with iodine-125 implants. Int J Radiat Oncol Biol Phys 23:321–326PubMedGoogle Scholar
  26. 26.
    Aiken AH, Chang SM, Larson D et al (2008) Longitudinal magnetic resonance imaging features of glioblastoma multiforme treated with radiotherapy with or without brachytherapy. Int J Radiat Oncol Biol Phys 72:1340–1346PubMedGoogle Scholar
  27. 27.
    Albert FK, Forsting M, Sartor K et al (1994) Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 34:45–60PubMedGoogle Scholar
  28. 28.
    Alexander E, Loeffler JS (1998) Radiosurgery for primary malignant brain tumors. Semin Surg Oncol 14:43–52PubMedGoogle Scholar
  29. 29.
    Anderson MD, Hamza MA, Hess KR, Puduvalli VK (2014) Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro Oncol 16:823–828PubMedPubMedCentralGoogle Scholar
  30. 30.
    Antoni D, Jastaniah Z, Haoming QC et al (2016) Patterns of relapse in patients with high grade glioma receiving combined treatments including stereotactic re-irradiation for a first relapse. Cancer Radiother 20:282–291PubMedGoogle Scholar
  31. 31.
    Aydin H, Sillenberg I, von Lieven H (2001) Patterns of failure following CT-based 3-D irradiation for malignant glioma. Strahlenther Onkol 177:424–431PubMedGoogle Scholar
  32. 32.
    Balducci M, Apicella G, Manfrida S et al (2010) Single-arm phase II study of conformal radiation therapy and temozolomide plus fractionated stereotactic conformal boost in high-grade gliomas: final report. Strahlenther Onkol 186:558–564PubMedGoogle Scholar
  33. 33.
    Bashir R, Hochberg F, Oot R (1988) Regrowth patterns of glioblastoma multiforme related to planning of interstitial brachytherapy radiation fields. Neurosurgery 23:27–30PubMedGoogle Scholar
  34. 34.
    Becker G, Hofmann E, Woydt M et al (1999) Postoperative neuroimaging of high-grade gliomas: comparison of transcranial sonography, magnetic resonance imaging, and computed tomography. Neurosurgery 44:469–477PubMedGoogle Scholar
  35. 35.
    Bernstein M, Laperriere N, Glen J et al (1994) Brachytherapy for recurrent malignant astrocytoma. Int J Radiat Oncol Biol Phys 30:1213–1217PubMedGoogle Scholar
  36. 36.
    Biswas A, Kumar N, Kumar P et al (2011) Primary gliosarcoma-clinical experience from a regional cancer centre in north India. Br J Neurosurg 25:723–729PubMedGoogle Scholar
  37. 37.
    Bloch O, Safaee M, Sun MZ et al (2013) Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 115:1795–1801PubMedPubMedCentralGoogle Scholar
  38. 38.
    Bokstein F, Kovner F, Blumenthal DT et al (2008) A common sense approach to radiotherapy planning of glioblastoma multiforme situated in the temporal lobe. Int J Radiat Oncol Biol Phys 72:900–904PubMedGoogle Scholar
  39. 39.
    Buglione M, Pedretti S, Poliani PL et al (2016) Pattern of relapse of glioblastoma multiforme treated with radical radio-chemotherapy: could a margin reduction be proposed? J Neurooncol 128:303–312PubMedGoogle Scholar
  40. 40.
    Burger MC, Mildenberger IC, Wagner M et al (2017) Bevacizumab for patients with recurrent gliomas presenting with a gliomatosis cerebri growth pattern. Int J Mol Sci 18:E726PubMedGoogle Scholar
  41. 41.
    Burger PC, Dubois PJ, Schold SC et al (1983) Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg 58:159–169PubMedGoogle Scholar
  42. 42.
    Chamberlain MC, Barba D, Kormanik P, Shea WM (1994) Stereotactic radiosurgery for recurrent gliomas. Cancer 74:1342–1347PubMedGoogle Scholar
  43. 43.
    Chamberlain MC (2011) Radiographic patterns of relapse in glioblastoma. J Neurooncol 101:319–323PubMedGoogle Scholar
  44. 44.
    Champ CE, Siglin J, Mishra MV et al (2012) Evaluating changes in radiation treatment volumes from post-operative to same-day planning MRI in High-grade gliomas. Radiat Oncol 7:220PubMedPubMedCentralGoogle Scholar
  45. 45.
    Chan DTM, Hsieh SYP, Kam MKM et al (2016) Pattern of recurrence and factors associated with cerebrospinal fluid dissemination of glioblastoma in Chinese patients. Surg Neurol Int 7:92PubMedPubMedCentralGoogle Scholar
  46. 46.
    Chan JL, Lee SW, Fraass BA et al (2002) Survival and failure patterns of high-grade gliomas after three-dimensional conformal radiotherapy. J Clin Oncol 20:1635–1642PubMedGoogle Scholar
  47. 47.
    Chang EL, Akyurek S, Avalos T et al (2007) Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma. Int J Radiat Oncol Biol Phys 68:144–150PubMedGoogle Scholar
  48. 48.
    Chen L, Chaichana KL, Kleinberg L et al (2015) Glioblastoma recurrence patterns near neural stem cell regions. Radiother Oncol 116:294–300PubMedPubMedCentralGoogle Scholar
  49. 49.
    Cho KH, Kim J-Y, Lee SH et al (2010) Simultaneous integrated boost intensity-modulated radiotherapy in patients with high-grade gliomas. Int J Radiat Oncol Biol Phys 78:390–397PubMedGoogle Scholar
  50. 50.
    Choucair AK, Levin VA, Gutin PH et al (1986) Development of multiple lesions during radiation therapy and chemotherapy in patients with gliomas. J Neurosurg 65:654–658PubMedGoogle Scholar
  51. 51.
    Colen RR, Zinn PO, Hazany S et al (2011) Magnetic resonance imaging appearance and changes on intracavitary Gliadel wafer placement: a pilot study. World J Radiol 3:266–272PubMedPubMedCentralGoogle Scholar
  52. 52.
    Desjardins A, Reardon DA, Coan A et al (2012) Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer 118:1302–1312PubMedGoogle Scholar
  53. 53.
    Dobelbower MC, Burnett Iii OL, Nordal RA et al (2011) Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide. J Med Imaging Radiat Oncol 55:77–81PubMedGoogle Scholar
  54. 54.
    Dörner L, Mustafa A, Rohr A et al (2013) Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma. J Clin Neurosci 20:429–434PubMedGoogle Scholar
  55. 55.
    Douglas JG, Stelzer KJ, Mankoff DA et al (2006) [F-18]-fluorodeoxyglucose positron emission tomography for targeting radiation dose escalation for patients with glioblastoma multiforme: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 64:886–891PubMedGoogle Scholar
  56. 56.
    Eisele G, Wick A, Eisele A-C et al (2014) Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. J Neurooncol 117:141–145PubMedGoogle Scholar
  57. 57.
    Ekinci G, Akpinar IN, Baltacioğlu F et al (2003) Early-postoperative magnetic resonance imaging in glial tumors: prediction of tumor regrowth and recurrence. Eur J Radiol 45:99–107PubMedGoogle Scholar
  58. 58.
    Elson A, Paulson E, Bovi J et al (2015) Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme. J Neurooncol 123:179–188PubMedGoogle Scholar
  59. 59.
    Elzinga G, Wong ET (2014) Resolution of cystic enhancement to add-on tumor treating electric fields for recurrent glioblastoma after incomplete response to bevacizumab. Case Rep Neurol 6:109–115PubMedPubMedCentralGoogle Scholar
  60. 60.
    Farina P, Tabouret E, Lehmann P et al (2017) Relationship between magnetic resonance imaging characteristics and plasmatic levels of MMP2 and MMP9 in patients with recurrent high-grade gliomas treated by Bevacizumab and Irinotecan. J Neurooncol 132:433–437PubMedGoogle Scholar
  61. 61.
    Forsting M, Albert FK, Kunze S et al (1993) Extirpation of glioblastomas: MR and CT follow-up of residual tumor and regrowth patterns. Am J Neuroradiol 14:77–87PubMedGoogle Scholar
  62. 62.
    Gállego Pérez-Larraya J, Lahutte M, Petrirena G et al (2012) Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative analysis of the Macdonald, RECIST, RANO, and RECIST + F criteria. Neuro Oncol 14:667–673PubMedGoogle Scholar
  63. 63.
    Garden AS, Maor MH, Yung WK et al (1991) Outcome and patterns of failure following limited-volume irradiation for malignant astrocytomas. Radiother Oncol 20:99–110PubMedGoogle Scholar
  64. 64.
    Gaspar LE, Fisher BJ, Macdonald DR et al (1992) Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. Int J Radiat Oncol Biol Phys 24:55–57PubMedGoogle Scholar
  65. 65.
    Gebhardt BJ, Dobelbower MC, Ennis WH et al (2014) Patterns of failure for glioblastoma multiforme following limited-margin radiation and concurrent temozolomide. Radiat Oncol 9:130PubMedPubMedCentralGoogle Scholar
  66. 66.
    Giese A, Kucinski T, Knopp U et al (2004) Pattern of recurrence following local chemotherapy with biodegradable carmustine (BCNU) implants in patients with glioblastoma. J Neurooncol 66:351–360PubMedGoogle Scholar
  67. 67.
    Gobitti C, Borsatti E, Arcicasa M et al (2011) Treatment of recurrent high-grade gliomas with GliaSite brachytherapy: a prospective mono-institutional Italian experience. Tumori 97:614–619PubMedGoogle Scholar
  68. 68.
    Gunjur A, Bressel M, Ryan G (2012) The addition of temozolomide does not change the pattern of progression of glioblastoma multiforme post-radiotherapy. J Med Imaging Radiat Oncol 56:567–573PubMedGoogle Scholar
  69. 69.
    Halligan JB, Stelzer KJ, Rostomily RC et al (1996) Operation and permanent low activity 125I brachytheraphy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 35:541–547PubMedGoogle Scholar
  70. 70.
    Heros DO, Renkens K, Kasdon DL, Adelman LS (1988) Patterns of recurrence in glioma patients after interstitial irradiation and chemotherapy: report of three cases. Neurosurgery 22:474–478PubMedGoogle Scholar
  71. 71.
    Hess CF, Schaaf JC, Kortmann RD et al (1994) Malignant glioma: patterns of failure following individually tailored limited volume irradiation. Radiother Oncol 30:146–149PubMedGoogle Scholar
  72. 72.
    Houston SC, Crocker IR, Brat DJ, Olson JJ (2000) Extraneural metastatic glioblastoma after interstitial brachytherapy. Int J Radiat Oncol Biol Phys 48:831–836PubMedGoogle Scholar
  73. 73.
    Iuchi T, Hatano K, Kodama T et al (2014) Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys 88:793–800PubMedGoogle Scholar
  74. 74.
    Iuchi T, Hatano K, Narita Y et al (2006) Hypofractionated high-dose irradiation for the treatment of malignant astrocytomas using simultaneous integrated boost technique by IMRT. Int J Radiat Oncol Biol Phys 64:1317–1324PubMedGoogle Scholar
  75. 75.
    Iwamoto FM, Abrey LE, Beal K et al (2009) Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 73:1200–1206PubMedPubMedCentralGoogle Scholar
  76. 76.
    Jastaniyah N, Murtha A, Pervez N et al (2013) Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme. Radiat Oncol 8:38PubMedPubMedCentralGoogle Scholar
  77. 77.
    Jia A, Pannullo SC, Minkowitz S et al (2016) Innovative hypofractionated stereotactic regimen achieves excellent local control with no radiation necrosis: promising results in the management of patients with small recurrent inoperable GBM. Cureus 8:e536PubMedPubMedCentralGoogle Scholar
  78. 78.
    Kim BR, Choi SH, Yun TJ et al (2016) MR Imaging analysis of non-measurable enhancing lesions newly appearing after concomitant chemoradiotherapy in glioblastoma patients for prognosis prediction. PLoS ONE 11:e0166096PubMedPubMedCentralGoogle Scholar
  79. 79.
    Kim BS, Kim SK, Choi SH et al (2015) Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas. J Neurooncol 124:101–110PubMedGoogle Scholar
  80. 80.
    Kim C-S, Jung S, Jung T-Y et al (2011) Characterization of invading glioma cells using molecular analysis of leading-edge tissue. J Korean Neurosurg Soc 50:157–165PubMedPubMedCentralGoogle Scholar
  81. 81.
    Kimura M, Lee Y, Miller R, Castillo M (2013) Glioblastoma multiforme: relationship to subventricular zone and recurrence. Neuroradiol J 26:542–547PubMedPubMedCentralGoogle Scholar
  82. 82.
    Konishi Y, Muragaki Y, Iseki H et al (2012) Patterns of intracranial glioblastoma recurrence after aggressive surgical resection and adjuvant management: retrospective analysis of 43 cases. Neurol Med Chir 52:577–586Google Scholar
  83. 83.
    Kyritsis AP, Levin VA, Yung WK, Leeds NE (1993) Imaging patterns of multifocal gliomas. Eur J Radiol 16:163–170PubMedGoogle Scholar
  84. 84.
    Larson DA, Prados M, Lamborn KR et al (2002) Phase II study of high central dose Gamma Knife radiosurgery and marimastat in patients with recurrent malignant glioma. Int J Radiat Oncol Biol Phys 54:1397–1404PubMedGoogle Scholar
  85. 85.
    Lee IH, Piert M, Gomez-Hassan D et al (2009) Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme. Int J Radiat Oncol Biol Phys 73:479–485PubMedGoogle Scholar
  86. 86.
    Lee SW, Fraass BA, Marsh LH et al (1999) Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 43:79–88PubMedGoogle Scholar
  87. 87.
    Liang BC, Thornton AF, Sandler HM, Greenberg HS (1991) Malignant astrocytomas: focal tumor recurrence after focal external beam radiation therapy. J Neurosurg 75:559–563PubMedGoogle Scholar
  88. 88.
    Lim DA, Cha S, Mayo MC et al (2007) Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol 9:424–429PubMedPubMedCentralGoogle Scholar
  89. 89.
    Loeffler JS, Alexander E, Hochberg FH et al (1990) Clinical patterns of failure following stereotactic interstitial irradiation for malignant gliomas. Int J Radiat Oncol Biol Phys 19:1455–1462PubMedGoogle Scholar
  90. 90.
    Majós C, Cos M, Castañer S et al (2016) Preradiotherapy MR imaging: a prospective pilot study of the usefulness of performing an MR examination shortly before radiation therapy in patients with glioblastoma. Am J Neuroradiol 37:2224–2230PubMedGoogle Scholar
  91. 91.
    Mamo A, Baig A, Azam M et al (2016) Progression pattern and adverse events with bevacizumab in glioblastoma. Curr Oncol 23:e468–e471PubMedPubMedCentralGoogle Scholar
  92. 92.
    Masciopinto JE, Levin AB, Mehta MP, Rhode BS (1995) Stereotactic radiosurgery for glioblastoma: a final report of 31 patients. J Neurosurg 82:530–535PubMedGoogle Scholar
  93. 93.
    Massey V, Wallner KE (1990) Patterns of second recurrence of malignant astrocytomas. Int J Radiat Oncol Biol Phys 18:395–398PubMedGoogle Scholar
  94. 94.
    Matsuda M, Ishikawa E, Yamamoto T et al (2017) Efficacy of bevacizumab therapy in recurrent malignant gliomas in relation to the prior recurrence pattern or tumor location. J Clin Neurosci 40:115–119PubMedGoogle Scholar
  95. 95.
    Matsuda M, Yamamoto T, Kumada H et al (2009) Dose distribution and clinical response of glioblastoma treated with boron neutron capture therapy. Appl Radiat Isot 67:S19–S21PubMedGoogle Scholar
  96. 96.
    McDonald MW, Shu H-KG, Curran WJ, Crocker IR (2011) Pattern of failure after limited margin radiotherapy and temozolomide for glioblastoma. Int J Radiat Oncol Biol Phys 79:130–136PubMedGoogle Scholar
  97. 97.
    Mehta MP, Masciopinto J, Rozental J et al (1994) Stereotactic radiosurgery for glioblastoma multiforme: report of a prospective study evaluating prognostic factors and analyzing long-term survival advantage. Int J Radiat Oncol Biol Phys 30:541–549PubMedGoogle Scholar
  98. 98.
    Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N et al (2015) Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? J Neurooncol 123:141–150PubMedPubMedCentralGoogle Scholar
  99. 99.
    Milano MT, Okunieff P, Donatello RS et al (2010) Patterns and timing of recurrence after temozolomide-based chemoradiation for glioblastoma. Int J Radiat Oncol Biol Phys 78:1147–1155PubMedGoogle Scholar
  100. 100.
    Minniti G, Amelio D, Amichetti M et al (2010) Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide. Radiother Oncol 97:377–381PubMedGoogle Scholar
  101. 101.
    Monjazeb AM, Ayala D, Jensen C et al (2012) A phase I dose escalation study of hypofractionated IMRT field-in-field boost for newly diagnosed glioblastoma multiforme. Int J Radiat Oncol Biol Phys 82:743–748PubMedGoogle Scholar
  102. 102.
    Murakami R, Hirai T, Nakamura H et al (2012) Recurrence patterns of glioblastoma treated with postoperative radiation therapy: relationship between extent of resection and progression-free interval. Jpn J Radiol 30:193–197PubMedGoogle Scholar
  103. 103.
    Nakagawa K, Aoki Y, Fujimaki T et al (1998) High-dose conformal radiotherapy influenced the pattern of failure but did not improve survival in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 40:1141–1149PubMedGoogle Scholar
  104. 104.
    Narayana A, Kelly P, Golfinos J et al (2009) Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg 110:173–180PubMedGoogle Scholar
  105. 105.
    Narayana A, Kunnakkat SD, Medabalmi P et al (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 82:77–82PubMedGoogle Scholar
  106. 106.
    Narayana A, Golfinos JG, Fischer I et al (2008) Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int J Radiat Oncol Biol Phys 72:383–389PubMedGoogle Scholar
  107. 107.
    Narayana A, Gruber D, Kunnakkat S et al (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345PubMedGoogle Scholar
  108. 108.
    Narayana A, Perretta D, Kunnakkat S et al (2011) Invasion is not an independent prognostic factor in high-grade glioma. J Cancer Res Ther 7:331–335PubMedGoogle Scholar
  109. 109.
    Nestler U, Lutz K, Pichlmeier U et al (2015) Anatomic features of glioblastoma and their potential impact on survival. Acta Neurochir 157:179–186PubMedGoogle Scholar
  110. 110.
    Niyazi M, Jansen NL, Rottler M et al (2014) Recurrence pattern analysis after re-irradiation with bevacizumab in recurrent malignant glioma patients. Radiat Oncol 9:299PubMedPubMedCentralGoogle Scholar
  111. 111.
    Niyazi M, Schnell O, Suchorska B et al (2012) FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status. Radiother Oncol 104:78–82PubMedGoogle Scholar
  112. 112.
    Norden AD, Young GS, Setayesh K et al (2008) Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 70:779–787PubMedGoogle Scholar
  113. 113.
    Nowosielski M, Wiestler B, Goebel G et al (2014) Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma. Neurology 82:1684–1692PubMedGoogle Scholar
  114. 114.
    Ogura K, Mizowaki T, Arakawa Y et al (2013) Initial and cumulative recurrence patterns of glioblastoma after temozolomide-based chemoradiotherapy and salvage treatment: a retrospective cohort study in a single institution. Radiat Oncol 8:97PubMedPubMedCentralGoogle Scholar
  115. 115.
    Oh J, Sahgal A, Sanghera P et al (2011) Glioblastoma: patterns of recurrence and efficacy of salvage treatments. Can J Neurol Sci 38:621–625PubMedGoogle Scholar
  116. 116.
    Oppitz U, Maessen D, Zunterer H et al (1999) 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol 53:53–57PubMedGoogle Scholar
  117. 117.
    Pan H, Alksne J, Mundt AJ et al (2012) Patterns of imaging failures in glioblastoma patients treated with chemoradiation: a retrospective study. Med Oncol 29:2040–2045PubMedGoogle Scholar
  118. 118.
    Panet-Raymond V, Souhami L, Roberge D et al (2009) Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis. Int J Radiat Oncol Biol Phys 73:473–478PubMedGoogle Scholar
  119. 119.
    Park I, Tamai G, Lee MC et al (2007) Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings. Int J Radiat Oncol Biol Phys 69:381–389PubMedPubMedCentralGoogle Scholar
  120. 120.
    Petrecca K, Guiot M-C, Panet-Raymond V, Souhami L (2013) Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma. J Neurooncol 111:19–23PubMedGoogle Scholar
  121. 121.
    Piroth MD, Galldiks N, Pinkawa M et al (2016) Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume. Radiat Oncol 11:87PubMedPubMedCentralGoogle Scholar
  122. 122.
    Pope WB, Xia Q, Paton VE et al (2011) Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab. Neurology 76:432–437PubMedGoogle Scholar
  123. 123.
    Price SJ, Jena R, Burnet NG et al (2007) Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol 17:1675–1684PubMedGoogle Scholar
  124. 124.
    Puchner MJA, Giese A, Lohmann F, Cristante L (2004) High-dose tamoxifen treatment increases the incidence of multifocal tumor recurrences in glioblastoma patients. Anticancer Res 24:4195–4203PubMedGoogle Scholar
  125. 125.
    Raizer JJ, Grimm S, Chamberlain MC et al (2010) A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer 116:5297–5305PubMedGoogle Scholar
  126. 126.
    Rostomily RC, Spence AM, Duong D et al (1994) Multimodality management of recurrent adult malignant gliomas: results of a phase II multiagent chemotherapy study and analysis of cytoreductive surgery. Neurosurgery 35:378–388 (discussion 388)PubMedGoogle Scholar
  127. 127.
    Schaub C, Greschus S, Seifert M et al (2013) FLAIR-only progression in bevacizumab-treated relapsing glioblastoma does not predict short survival. Oncology 85:191–195PubMedGoogle Scholar
  128. 128.
    Schupak K, Malkin M, Anderson L et al (1995) The relationship between the technical accuracy of stereotactic interstitial implantation for high grade gliomas and the pattern of tumor recurrence. Int J Radiat Oncol Biol Phys 32:1167–1176PubMedGoogle Scholar
  129. 129.
    Shapiro LQ, Beal K, Goenka A et al (2013) Patterns of failure after concurrent bevacizumab and hypofractionated stereotactic radiation therapy for recurrent high-grade glioma. Int J Radiat Oncol Biol Phys 85:636–642PubMedGoogle Scholar
  130. 130.
    Sharma RR, Singh DP, Pathak A et al (2003) Local control of high-grade gliomas with limited volume irradiation versus whole brain irradiation. Neurol India 51:512–517PubMedGoogle Scholar
  131. 131.
    Sherriff J, Tamangani J, Senthil L et al (2013) Patterns of relapse in glioblastoma multiforme following concomitant chemoradiotherapy with temozolomide. Br J Radiol 86:20120414PubMedPubMedCentralGoogle Scholar
  132. 132.
    Shibahara I, Sonoda Y, Saito R et al (2013) The expression status of CD133 is associated with the pattern and timing of primary glioblastoma recurrence. Neuro Oncol 15:1151–1159PubMedPubMedCentralGoogle Scholar
  133. 133.
    Shields LBE, Kadner R, Vitaz TW, Spalding AC (2013) Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme. Radiat Oncol 8:101PubMedPubMedCentralGoogle Scholar
  134. 134.
    Shimato S, Nishizawa T, Ohshima T et al (2016) Patterns of recurrence after resection of malignant gliomas With BCNU wafer implants: retrospective review in a single institution. World Neurosurg 90:340–347PubMedGoogle Scholar
  135. 135.
    Showalter TN, Andrel J, Andrews DW et al (2007) Multifocal glioblastoma multiforme: prognostic factors and patterns of progression. Int J Radiat Oncol Biol Phys 69:820–824PubMedGoogle Scholar
  136. 136.
    Soffietti R, Trevisan E, Bertero L et al (2014) Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol 116:533–541PubMedGoogle Scholar
  137. 137.
    Souhami L, Seiferheld W, Brachman D et al (2004) Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93 - 05 protocol. Int J Radiat Oncol Biol Phys 60:853–860PubMedGoogle Scholar
  138. 138.
    Stall B, Zach L, Ning H et al (2010) Comparison of T2 and FLAIR imaging for target delineation in high grade gliomas. Radiat Oncol 5:5PubMedPubMedCentralGoogle Scholar
  139. 139.
    Stummer W, Beck T, Beyer W et al (2008) Long-sustaining response in a patient with non-resectable, distant recurrence of glioblastoma multiforme treated by interstitial photodynamic therapy using 5-ALA: case report. J Neurooncol 87:103–109PubMedGoogle Scholar
  140. 140.
    Suzuki M, Nakamatsu K, Kanamori S et al (2003) Feasibility study of the simultaneous integrated boost (SIB) method for malignant gliomas using intensity-modulated radiotherapy (IMRT). Jpn J Clin Oncol 33:271–277PubMedGoogle Scholar
  141. 141.
    Takano S, Mashiko R, Osuka S et al (2010) Detection of failure of bevacizumab treatment for malignant glioma based on urinary matrix metalloproteinase activity. Brain Tumor Pathol 27:89–94PubMedGoogle Scholar
  142. 142.
    Tang W, Wang X, Chen Y et al (2015) CXCL12 and CXCR4 as predictive biomarkers of glioma recurrence pattern after total resection. Pathol Biol 63:190–198PubMedGoogle Scholar
  143. 143.
    Tejada S, Aldave G, Marigil M et al (2014) Factors associated with a higher rate of distant failure after primary treatment for glioblastoma. J Neurooncol 116:169–175PubMedGoogle Scholar
  144. 144.
    Torok JA, Wegner RE, Mintz AH et al (2011) Re-irradiation with radiosurgery for recurrent glioblastoma multiforme. Technol Cancer Res Treat 10:253–258PubMedGoogle Scholar
  145. 145.
    Trifiletti DM, Hill C, Garda A et al (2017) Multilesion glioblastoma multiforme in the modern chemo-radiotherapy era: an analysis of pattern of failure and overall survival. J Radiat Oncol 6:57–63Google Scholar
  146. 146.
    Tsien CI, Brown D, Normolle D et al (2012) Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma. Clin Cancer Res 18:273–279PubMedGoogle Scholar
  147. 147.
    Tsuboi K, Yoshii Y, Nakagawa K, Maki Y (1986) Regrowth patterns of supratentorial gliomas: estimation from computed tomographic scans. Neurosurgery 19:946–951PubMedGoogle Scholar
  148. 148.
    Tuettenberg J, Grobholz R, Seiz M et al (2009) Recurrence pattern in glioblastoma multiforme patients treated with anti-angiogenic chemotherapy. J Cancer Res Clin Oncol 135:1239–1244PubMedGoogle Scholar
  149. 149.
    Uehara K, Sasayama T, Miyawaki D et al (2012) Patterns of failure after multimodal treatments for high-grade glioma: effectiveness of MIB-1 labeling index. Radiat Oncol 7:104PubMedPubMedCentralGoogle Scholar
  150. 150.
    Wallner KE, Galicich JH, Krol G et al (1989) Patterns of failure following treatment for glioblastoma multiforme and anaplastic astrocytoma. Int J Radiat Oncol Biol Phys 16:1405–1409PubMedGoogle Scholar
  151. 151.
    Weber DC, Casanova N, Zilli T et al (2009) Recurrence pattern after [(18)F]fluoroethyltyrosine-positron emission tomography-guided radiotherapy for high-grade glioma: a prospective study. Radiother Oncol 93:586–592PubMedGoogle Scholar
  152. 152.
    Welsh J, Sanan A, Gabayan AJ et al (2007) GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study. Int J Radiat Oncol Biol Phys 68:159–165PubMedGoogle Scholar
  153. 153.
    Wick W, Chinot OL, Bendszus M et al (2016) Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol 18:1434–1441PubMedPubMedCentralGoogle Scholar
  154. 154.
    Wick W, Stupp R, Beule A-C et al (2008) A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro Oncol 10:1019–1024PubMedPubMedCentralGoogle Scholar
  155. 155.
    Wick A, Dörner N, Schäfer N et al (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69:586–592.  https://doi.org/10.1002/ana.22336 PubMedGoogle Scholar
  156. 156.
    Wismeth C, Dudel C, Pascher C et al (2010) Transcranial electro-hyperthermia combined with alkylating chemotherapy in patients with relapsed high-grade gliomas: phase I clinical results. J Neurooncol 98:395–405PubMedGoogle Scholar
  157. 157.
    Yanagihara TK, Grinband J, Rowley J et al (2016) A simple automated method for detecting recurrence in high-grade glioma. Am J Neuroradiol 37:2019–2025Google Scholar
  158. 158.
    Yoo R-E, Choi SH, Kim TM et al (2015) Independent poor prognostic factors for true progression after radiation therapy and concomitant temozolomide in patients with glioblastoma: subependymal enhancement and low ADC value. Am J Neuroradiol 36:1846–1852PubMedGoogle Scholar
  159. 159.
    Young RJ, Gupta A, Shah AD et al (2011) Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma. Neurology 76:1918–1924PubMedPubMedCentralGoogle Scholar
  160. 160.
    Zhou X, Liao X, Zhang B et al (2016) Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy. Mol Clin Oncol 5:289–294PubMedPubMedCentralGoogle Scholar
  161. 161.
    Zuniga RM, Torcuator R, Jain R et al (2009) Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan. J Neurooncol 91:329–336PubMedGoogle Scholar
  162. 162.
    Zuniga RM, Torcuator R, Jain R et al (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. J Neurooncol 99:237–242PubMedGoogle Scholar
  163. 163.
    Sneed PK, Gutin PH, Larson DA et al (1994) Patterns of recurrence of glioblastoma multiforme after external irradiation followed by implant boost. Int J Radiat Oncol Biol Phys 29:719–727PubMedGoogle Scholar
  164. 164.
    Adeberg S, König L, Bostel T et al (2014) Glioblastoma recurrence patterns after radiation therapy with regard to the subventricular zone. Int J Radiat Oncol Biol Phys 90:886–893PubMedGoogle Scholar
  165. 165.
    Kim J-H, Jung T-Y, Hwang EC et al (2017) Disease progression patterns of bevacizumab responders with recurrent malignant gliomas. Oncol Lett 14:3529–3535PubMedPubMedCentralGoogle Scholar
  166. 166.
    Macdonald DR, Cascino TL, Schold SC, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  167. 167.
    Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247PubMedGoogle Scholar
  168. 168.
    Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453–461PubMedGoogle Scholar
  169. 169.
    Taal W, Brandsma D, de Bruin HG et al (2008) Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide. Cancer 113:405–410PubMedGoogle Scholar
  170. 170.
    Shapiro WR (1999) Current therapy for brain tumors: back to the future. Arch Neurol 56:429–432PubMedGoogle Scholar
  171. 171.
    Price SJ, Jena R, Burnet NG et al (2006) Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. Am J Neuroradiol 27:1969–1974PubMedGoogle Scholar
  172. 172.
    Price MS, Matys DT, Joannides DA et al (2017) OP04. Predicting sites of treatment failure and tumour recurrence in the invasive margin of glioblastomas (PRAM-GBM)—trial. Neuro Oncol 19:i24–i25PubMedCentralGoogle Scholar
  173. 173.
    Macleod MR, Michie S, Roberts I et al (2014) Biomedical research: increasing value, reducing waste. Lancet 383:101–104PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Rory J. Piper
    • 1
  • Keerthi K. Senthil
    • 1
  • Jiun-Lin Yan
    • 1
  • Stephen J. Price
    • 1
  1. 1.Cambridge Brain Tumour Imaging Laboratory, Division of Neurosurgery, Department of Clinical NeurosciencesUniversity of CambridgeCambridgeUK

Personalised recommendations